secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biohaven Ltd. (BHVN)
CIK:        0001935979
Form:       8-K
Filed at:   2024-04-15T23:59:59+00:00
Accession:  0001935979-24-000031
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biohaven presents BHV-1300 Ph1 SAD data: safe, dose-dependent IgG lowering in 16 subjects
--------------------------------------------------------------------------------

- 16 subjects completed two dosing cohorts; no SAEs, only mild AEs unrelated to drug.
- Preliminary dose- and time-dependent IgG lowering observed; IgG1/2/4 reduction greater than IgG3.
- BHV-1300 designed to spare IgG3; data consistent with preclinical nonhuman primate models.
- Further program update planned at Company's R&D Day on May 29, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1935979/000193597924000031/0001935979-24-000031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1935979/000193597924000031/bhvn-20240415.htm
  HTML page:      https://secwatch.observer/filing/0001935979-24-000031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer